MyoKardia, Inc. is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical products, services, research and therapies.
The company stated in the following press release that they conduct pre-clinical trials of their drugs on animals.
“Based on preclinical research across multiple animal models, MYK-491 may hold potential for controlled increases in the heart’s contractility with minimal impact on diastole or relaxation.” Read the following article
MyoKardia, Inc. is a biopharmaceutical company. It engages in the discovery, development, and commercialization of targeted therapies for the treatment of cardiovascular diseases. The company focuses on the treatment of heritable cardiomyopathies, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. It offers MYK-46, an orally-administered small molecule designed to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy. The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. [Source: MarketWatch]
Company Website: http://www.myokardia.com